Navigating the mCRPC Landscape: Exploring Key Clinical Decision Points

Chairperson:

Fred Saad¹

Speakers:

Gero Kramer,² Bertrand Tombal,³ Jürgen Gschwend⁴

1. University of Montreal, Montreal, Canada
2. Medical University of Vienna, Vienna, Austria
3. Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
4. Rechts der Isar Medical Center, Technical University Munich, Munich, Germany

Disclosure:

Professor Saad has received advisory board and/or research funding from Abbott, Amgen, Astellas, Bayer, Janssen, Millennium, Novartis, and Sanofi. Professor Kramer has received scientific advisory board/honoraria from Sanofi, Bayer, Janssen, Takeda, Astellas, Ipsen, and Pfizer. Professor Tombal has acted as an investigator for Astellas, Bayer, Ferring, Janssen, Medivation, Sanofi, and Takeda, and as a paid consultant or speaker for Amgen, Astellas, Bayer, Ferring, Medivation, Sanofi, and Takeda. Professor Gschwend has received honoraria from Amgen, Astellas, Bayer, Janssen, Novartis, and PierreFabre, and advisory board fees from Amgen, Astellas, Bayer, BMS, Janssen, Novartis, Pfizer, Pierre-Fabre, Roche, and Teva.

Acknowledgements:

Writing assistance was provided by Dr Saroshi Amirthalingam, apothecom scopemedical Ltd.

Support:

The publication of this article was funded by Bayer. The views and opinions expressed are those of the authors and not necessarily of Bayer.

Citation:

EMJ Urol. 2015;3[2]:57-62. DOI/10.33590/emjurol/10312887. https://doi.org/10.33590/emjurol/10312887.

Keywords:

Urology, EAU17.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.